Apixaban, a direct orally active anticoagulant (selective, direct factor Xa inhibitor) is
approved for (primary) prevention of venous thromboembolism (VTE) in patients undergoing …

Apixaban (Eliquis™) is an orally active and selective direct inhibitor of factor Xa indicated for
twice-daily use in the EU for the prevention of venous thromboembolism (VTE) in adults who …

Apixaban (Eliquis™), an oral direct factor Xa inhibitor, is being developed by Bristol-Myers
Squibb and Pfizer as a therapy for the prevention and/or treatment of thrombotic disorders …

Anticoagulant prophylaxis for preventing venous thromboembolism (VTE) is a worldwide
established procedure in hip and knee replacement surgery. Despite available …

Objective: To provide a comprehensive review of the pharmacology, pharmacokinetics,
pharmacodynamics, clinical trial data, adverse effects, and drug interactions of apixaban …

Background: Apixaban is a novel oral factor Xa inhibitor that recently completed evaluation
in clinical trials for its use in the prevention of venous thromboembolism (VTE) in patients …

Introduction: Traditional oral anticoagulants, such as warfarin, are effective but require
frequent laboratory monitoring for dose adjustment and have several known interactions …

Background: New oral anticoagulants for thromboprophylaxis after hip or knee arthroplasty
have been given as fixed-dose regimens. Objective: To evaluate the consistency of the …

Abstract 192 Thromboprophylaxis after joint replacement surgery is evidence-based
standard care. Usually, when thromboprophylaxis regimens with new anticoagulants have …

Apixaban is an anticoagulant drug that acts by directly inhibiting coagulation factor Xa.
Unlike low-molecular-weight heparins and fondaparinux, apixaban can be taken orally; in …